InvIOs Selects INV501 Lead Candidate for IND-Enabling Studies in Glioblastoma and Melanoma

invIOs GmbH has announced the selection of INV501 as its lead candidate for IND-enabling studies in glioblastoma and melanoma. INV501, a novel small molecule, activates tumor-specific T cells. Patents for the program have been filed.

Preclinical testing in melanoma and breast cancer has been successful. Toxicology studies are in preparation, with glioblastoma testing in collaboration with the Dana-Farber Cancer Institute. INV501 effectively crosses the blood-brain barrier, enhancing its potential for brain cancer treatment.

Data supports INV501's strong anti-tumor responses and favorable pharmacokinetics. The compound's capacity for inducing T cell activation suggests a promising role in cancer immunotherapy. Further studies will investigate its mechanisms of action.